Tislelizumab Yields Comparable OS, Improves Responses Vs Sorafenib in HCC

Retrieved on: 2023-10-28 16:04:56

Tags for this article:

Orphan drugs

Chloroarenes

Hepatocellular carcinoma

Ramucirumab

Evofosfamide

sorafenib tosylate

Click the tags to see associated articles and topics

Tislelizumab Yields Comparable OS, Improves Responses Vs Sorafenib in HCC. View article details on HISWAI: https://www.cancernetwork.com/view/tislelizumab-yields-comparable-os-improves-responses-vs-sorafenib-in-hcc

Excerpt

... data analysis of a phase 1b/2 trial (NCT04524871). As of a data cutoff ... “This comprehensive analysis of more mature clinical data shows an even ...

Article found on: www.cancernetwork.com

View Original Article